Asston Pharmaceuticals

Asston Pharmaceuticals Limited - IPO

SME

Asston Pharmaceuticals IPO Details

Open Date
09 Jul 2025
Close Date
11 Jul 2025
Listing Date
16 Jul 2025
Issue Price
₹115 - ₹123
Face Value
₹10 per share
Lot Size
1000
GMP
₹25 (20.3%)
Issue Type
IPO
Listing On
BSE
Type
Book Built Issue
Share holding pre issue
6271360
Share holding post issue
8512360
Total Issue Size
22,41,000 shares (aggregating up to ₹27.56 Cr)
Fresh Issue
22,41,000 shares (aggregating up to ₹27.56 Cr)
Offer for Sale
-

Asston Pharmaceuticals IPO Subscription

Asston Pharmaceuticals IPO Application Wise Breakup

Asston Pharmaceuticals IPO Dates

  • 09 Jul 2025
    Opening dateOPD
  • 11 Jul 2025
    Closing dateCOD
  • 14 Jul 2025
    Basis of AllotmentBOA
  • 15 Jul 2025
    Initiation of RefundsIOR
  • 15 Jul 2025
    Credit of SharesCOS
  • 16 Jul 2025
    Listing dateLID

Asston Pharmaceuticals IPO Lot Size

ApplicationLotsSharesAmount
Individual Minimum22000₹246,000
Individual Maximum22000₹246,000
SHNI Minimum33000₹369,000
SHNI Maximum88000₹984,000
BHNI Minimum99000₹1,107,000

Asston Pharmaceuticals IPO Reservation

Promoter Holding

Pre Issue:68.76%
Post Issue:50.66%
Promoter Names:
Dr. Ashish Narayan Sakalkar, Saili Jayaram More, Sachin Chandrakant Badakh

Asston Pharmaceuticals IPO Valuations

ROE:50.56%
ROCE:51.25%
DEBT/EQUITY:0.68
RONW:40.36%
PAT MARGIN:17.27%
PRICE TO BOOK VALUE:12.07
EPS Pre IPO:6.90
EPS Post IPO:9.32
P/E Pre IPO:17.83
P/E Post IPO:13.2

Asston Pharmaceuticals Limited Financial Information

Period Ended31 May 202531 Mar 202531 Mar 202431 Mar 2023
Assets31.8328.1220.2613.69
Revenue6.2125.6115.847.19
Profit After Tax1.324.331.361.06
EBITDA1.936.162.551.52
Net Worth12.0410.726.391.99
Reserves and Surplus5.774.455.611.29
Total Borrowing7.837.266.825.25
Amount in ₹ Crore

About Asston Pharmaceuticals IPO

Incorporated in 2019, Asston Pharmaceuticals Limited is engaged in the business of pharmaceuticals, specializing in exporting healthcare products globally.

The company offers a diverse range of products, including tablets, capsules, sachets, and syrups. Its product portfolio encompasses various therapeutic categories, such as analgesics, antibiotics, antifungals, vitamins, and more.

The company manufactures pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis, primarily working on a principle-to-principle approach with various marketers.

The company is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing.

Products:

  • Albendazole USP 400 mg: Albendazole USP 400 mg refers to a higher dosage of Albendazole, a broad-spectrum anthelmintic (anti-worm) medication that is used to treat various parasitic worm infections.
  • Diclofenac 100 mg: Diclofenac 100 mg refers to a specific dosage of Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID).
  • Ibuprofen, paracetamol: Ibuprofen and Paracetamol (Acetaminophen) are two commonly used over-the-counter medications, often used to relieve pain and reduce fever.
  • Ferrovit Syrup: To treat vitamin and mineral deficiencies.

As of 3 July 2025, the company has 46 Permanent employees and 6 contractual employees in various departments.

 

Strength Of Asston Pharmaceuticals IPO

1. Formulation Expertise.

2. Experienced Promoters.

3. Wide range of Products.

4. Strategic Location.

5. Skilled Workforce.

6. Good relationship with contract manufacturers.

7. Quality Assurance.

8. Good relationship with clients in the export market.

9. Competitive Pricing.

10. Asset Light Model.

Risk Of Asston Pharmaceuticals IPO

1. The Company operates in pharmaceutical sector, which is extensively regulated, any failures on its part to comply with the existing and future statutory and/or regulatory requirements in the pharmaceutical sector could adversely affect its business, results of operations and financial condition.

2. The company operate its own manufacturing facility for pharmaceutical products; however for certain products other than tablets, the company relies on third-party manufacturers to procure the pharmaceutical products.

3. The company depends on the success of its relationships with the company customers. The company derives a significant part of its revenue from its major customers and the company does not have long-term contracts with these customers other than contracts with 2 customers for one year. If one or more of such customers choose not to source their requirements from it, the company business, financial condition and results of operations may be adversely affected.

4. The loss of contract manufacturing tie-ups and the low entry barrier for contract manufacturing can affect production, order intake, revenue, cash flow, and profitability. The absence of exclusive agreements increases the risk of delays or disruptions in order execution, further impacting business operations.

5. The company has substantial working capital expenditure and may requires additional financing to meet those requirements and have risk of receivables, which could have an adverse effect on its results of operations and financial condition.

6. The property used by the Company for the purpose of its Registered Office and factory is not owned by the company. Any termination of the relevant lease agreement in connection with such property or the company failures to renew the same could adversely affect its operations.

7. The company success largely depends upon the knowledge and experience of its Promoters, Directors, the company Key Managerial Personnel and Senior Management as well as its ability to attract and retain personnel with technical expertise. Any loss of the company Promoter, Directors, Key Managerial Personnel, Senior Management or its ability to attract and retain them and other personnel with technical expertise could adversely affect its business, financial condition and results of operations.

8. If the company is not able to attract and retain sufficient qualified and trained personnel at the Company which may adversely affect its business.

9. The company has been recently converted into public limited company and any non-compliance with the provisions of Companies Act, 2013 may attract penalties against the Company which could impact its financial and operational performance and reputation.

10. All its manufacturing facilities are situated at Ambernath, Thane, Maharashtra resulting in concentration in a single region. Any interruption for a significant period of time, in these facilities may in turn adversely affect its business, financial condition and results of operations.

Objectives Asston Pharmaceuticals IPO

1. Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit

2. Funding the incremental working capital requirements of the Company

3. Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company

4. General Corporate Purposes

Company Contact Details

Asston Pharmaceuticals Limited
4th Floor, Office No. A-431 Balaji Bhavan,
Plot No 42A Sector-11 CBD Belapur,
Navi Mumbai, Thane
Navi Mumbai, Maharashtra, 400614
Phone: +91 22 49731411
Email: info@asstonpharmaceuticals.com
Website: http://www.asstonpharmaceuticals.com/

Registrar Contact Details

Name: Maashitla Securities Private Limited
Phone: +91-11-45121795, +91-11-45121796

Lead Mangers

  1. Sobhagya Capital Options Ltd

Market Maker

  1. JSK Securities and Services Private Limited

Comments